Omni Bio Pharm Inc (OMBP) 0.2500 $OMBP
Omni Bio Announces Grant of New Use Patent in Europe
Marketwire - Thu May 08, 8:02AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications as well as the development of recombinant forms of AAT, today announced that it has received a Grant Notice from the European Patent Office for the use of AAT in reducing the risks of non-organ transplant rejection and graft versus host disease (GvHD) in patients who have received a cornea, bone marrow or pancreatic islet cell transplant. Patent applications covering similar claims have issued in Canada and are under review in the U.S.
Omni Bio Pharmaceutical elects Dr Bruce Forrest as CDO
M2 - Fri May 02, 6:14AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical (OTCQB:OMBP) disclosed on Thursday that Dr Bruce D Forrest has been named as its chief development officer.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Omni Bio Pharmaceutical Appoints Dr. Bruce Forrest to Chief Development Officer Role
Marketwire - Thu May 01, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Dr. Bruce D. Forrest to the position of Chief Development Officer.
Omni Bio Pharmaceutical Announces Publication of Its Pilot Study of Alpha-1 Antitrypsin in Type 1 Diabetes
Marketwire - Wed Apr 30, 8:01AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the publication of final results from its pilot study of AAT in patients with recent onset Type 1 diabetes (T1D) in the Journal of Clinical Endocrinology and Metabolism.
Gallus BioPharmaceuticals partners with Omni Bio Pharmaceutical for AAT Fc fusion protein
M2 - Wed Apr 30, 3:57AM CDT
Contract manufacturing company Gallus BioPharmaceuticals said on Tuesday that it has finalised its multi-stage AAT Fc fusion protein agreement with Omni Bio Pharmaceutical (OTCQB:OMBP), a biopharmaceutical company.
Gallus Enters Cell Line Optimization and Manufacturing Agreement With Omni Bio Pharmaceutical
Marketwire - Tue Apr 29, 1:00AM CDT
Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract development and manufacturing organization (CMO), and Omni Bio Pharmaceutical, Inc. (Omni Bio) (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, jointly announced finalization of a multi-stage manufacturing services agreement.
Omni Bio Pharmaceutical Announces $3 Million Private Financing Plan and New Investment Banking Services Advisor
Marketwire - Thu Apr 24, 8:02AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced finalization of a private financing arrangement led by its principal investor, Bohemian Investments LLC ("Bohemian", that establishes a credit facility for up to $3 million to support ongoing operations and execution of the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule (Fc AAT) that is being targeted for the treatment of Type 1 diabetes, graft versus host disease and various inflammatory conditions, including chronic gout. The most immediate use of proceeds will be for cell line optimization and product manufacturing scale-up work to be performed by a contract manufacturing partner soon-to-be announced.
Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Marketwire - Wed Nov 20, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced important results from new studies of its recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.
Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD".
Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.
Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.
Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.
Omni Bio Announces Grant of New Use Patent in Europe
Marketwire - Thu May 08, 8:02AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications as well as the development of recombinant forms of AAT, today announced that it has received a Grant Notice from the European Patent Office for the use of AAT in reducing the risks of non-organ transplant rejection and graft versus host disease (GvHD) in patients who have received a cornea, bone marrow or pancreatic islet cell transplant. Patent applications covering similar claims have issued in Canada and are under review in the U.S. Omni Bio Pharmaceutical elects Dr Bruce Forrest as CDO
M2 - Fri May 02, 6:14AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical (OTCQB:OMBP) disclosed on Thursday that Dr Bruce D Forrest has been named as its chief development officer.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Omni Bio Pharmaceutical Appoints Dr. Bruce Forrest to Chief Development Officer Role
Marketwire - Thu May 01, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Dr. Bruce D. Forrest to the position of Chief Development Officer. Omni Bio Pharmaceutical Announces Publication of Its Pilot Study of Alpha-1 Antitrypsin in Type 1 Diabetes
Marketwire - Wed Apr 30, 8:01AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the publication of final results from its pilot study of AAT in patients with recent onset Type 1 diabetes (T1D) in the Journal of Clinical Endocrinology and Metabolism. Gallus BioPharmaceuticals partners with Omni Bio Pharmaceutical for AAT Fc fusion protein
M2 - Wed Apr 30, 3:57AM CDT
Contract manufacturing company Gallus BioPharmaceuticals said on Tuesday that it has finalised its multi-stage AAT Fc fusion protein agreement with Omni Bio Pharmaceutical (OTCQB:OMBP), a biopharmaceutical company.
Gallus Enters Cell Line Optimization and Manufacturing Agreement With Omni Bio Pharmaceutical
Marketwire - Tue Apr 29, 1:00AM CDT
Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract development and manufacturing organization (CMO), and Omni Bio Pharmaceutical, Inc. (Omni Bio) (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, jointly announced finalization of a multi-stage manufacturing services agreement.
Omni Bio Pharmaceutical Announces $3 Million Private Financing Plan and New Investment Banking Services Advisor
Marketwire - Thu Apr 24, 8:02AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced finalization of a private financing arrangement led by its principal investor, Bohemian Investments LLC ("Bohemian", that establishes a credit facility for up to $3 million to support ongoing operations and execution of the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule (Fc AAT) that is being targeted for the treatment of Type 1 diabetes, graft versus host disease and various inflammatory conditions, including chronic gout. The most immediate use of proceeds will be for cell line optimization and product manufacturing scale-up work to be performed by a contract manufacturing partner soon-to-be announced. Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Marketwire - Wed Nov 20, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced important results from new studies of its recombinant molecule, Fc-AAT. Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013. Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD". Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT. Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013. Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider. Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009. 
